Results 101 to 110 of about 25,065,433 (389)

Correlation of serum IL-2 and IFN-γ levels with clinical prognosis of nasopharyngeal carcinoma patients and analysis of risk factors [PDF]

open access: yesJournal of Medical Biochemistry
Background: This study aims to investigate the correlation between serum levels of interleukin-2 (IL-2) and interferong (IFN-g) and the clinical prognosis of patients with nasopharyngeal carcinoma (NPC).
Guo Siquan   +5 more
doaj   +1 more source

Modeling of anti-tumor immune response: immunocorrective effect of weak centimeter electromagnetic waves [PDF]

open access: yesarXiv, 2005
We formulate the dynamical model for the anti-tumor immune response based on intercellular cytokine-mediated interactions with the interleukin-2 (IL-2) taken into account. The analysis shows that the expression level of tumor antigens on antigen presenting cells has a distinct influence on the tumor dynamics.
arxiv  

Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor

open access: yesJournal of Experimental Medicine, 1994
Interleukin 15 (IL-15) is a novel cytokine that has recently been cloned and expressed. Whereas it has no sequence homology with IL-2, IL- 15 interacts with components of the IL-2 receptor (IL-2R).
W. E. Carson   +9 more
semanticscholar   +1 more source

Human colon organoid differentiation from induced pluripotent stem cells using an improved method

open access: yesFEBS Letters, Volume 599, Issue 6, Page 912-924, March 2025.
We compared established protocols to differentiate induced pluripotent stem cells into colon organoids and found that activation of bone morphogenetic protein 2 signaling induced gene expression of colon‐specific markers. Adenovirus‐mediated transduction of the transcription factors HOXD13 or SATB2 further enhanced colonic gene expression, suggesting ...
I‐Ting Lee   +4 more
wiley   +1 more source

PD-1 signaling modulates interferon-γ production by Gamma Delta (γδ) T-Cells in response to leukemia

open access: yesOncoImmunology, 2019
Gamma delta (γδ) T-cell based immunotherapy is a promising concept for the treatment of hematologic malignancies. Not only in vitro but also in early phase clinical trials, zoledronic acid (Zol) and interleukin-2 (IL-2) have been successfully used to ...
Timm Hoeres   +4 more
doaj   +1 more source

An Empirical Study of Immune System Based On Bipartite Network [PDF]

open access: yesarXiv, 2007
Immune system is the most important defense system to resist human pathogens. In this paper we present an immune model with bipartite graphs theory. We collect data through COPE database and construct an immune cell- mediators network. The act degree distribution of this network is proved to be power-law, with index of 1.8.
arxiv  

Insights into the renal pathophysiology in Hermansky‐Pudlak syndrome‐1 from urinary extracellular vesicle proteomics and a new mouse model

open access: yesFEBS Letters, Volume 599, Issue 7, Page 1055-1074, April 2025.
Hermansky‐Pudlak syndrome type 1 (HPS‐1) is a rare, autosomal recessive disorder with poorly understood renal involvement. Urinary extracellular vesicle (uEV) proteomics and a novel Hps1 mouse model reveal mitochondrial abnormalities and lipid accumulation in HPS‐1 kidney proximal tubule cells. Serum ApoA1 correlates with kidney function in our patient
Dawn M. Maynard   +7 more
wiley   +1 more source

P21. INCORPORATION OF DECELLULARIZED EXTRACELLULAR MATRIX IN 3D-PRINTED GRAPHENE-BASED SCAFFOLDS FOR TREATMENT OF VOLUMETRIC MUSCLE LOSS

open access: yesPlastic and Reconstructive Surgery, Global Open, 2022
Carlos Serna, III, PhD   +7 more
doaj   +1 more source

Evaluation of IL-2 and IL-7 expression in patients with prostate cancer

open access: yesResearch in Molecular Medicine, 2019
Background: Prostate cancer is a biologically heterogeneous disease which has become the fifth leading cause of cancer-related deaths in men worldwide. Interleukins (ILs) display required inflammation moderator.
Faezeh Namazi   +3 more
doaj  

A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma

open access: yesOncoImmunology, 2018
Background: Approximately 50% of melanomas harbor BRAF mutations. Treatment with BRAF +/− MEK inhibition is associated with favorable changes in the tumor microenvironment thus providing the rationale for combining targeted agents with immunotherapy ...
Meghan J. Mooradian   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy